Standardizing preanalytical variables for molecular cytopathology

Cancer Cytopathology

Volumn 121, Issue 7, 2013, Pages 341-343

  Da Cunha Santos, Gilda ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FORMALDEHYDE; PARAFFIN;

ACCURACY; CARCINOMA CELL; COMPARATIVE STUDY; CROSS LINKING; CYTOPATHOLOGY; DNA EXTRACTION; EDITORIAL; GENOTYPE; HUMAN; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; MUTATIONAL ANALYSIS; PAPANICOLAOU TEST; PRIORITY JOURNAL; RELIABILITY; STAINING; TISSUE PREPARATION; CYTODIAGNOSIS; DIAGNOSTIC PROCEDURE; STANDARD;

CLINICAL LABORATORY TECHNIQUES; CYTODIAGNOSIS; HUMANS;

EID: 84884737197     PISSN: None     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.21290     Document Type: Editorial

References (12)

1. Saieg MA, Geddie WR, Boerner SL, Bailey D, Crump M, Cunha Santos G. EZH2 and CD79B mutational status over time in B-cell non-Hodgkin lymphomas detected by high-throughput sequencing using minimal samples. Cancer (Cancer Cytopathol). 2013;121:377-386.
2. Betz BL, Roh MH, Weigelin HC, et al. The application of molecular diagnostic studies interrogating EGFR and KRAS mutations to stained cytologic smears of lung carcinoma. Am J Clin Pathol. 2011;136:564-571.
3. Billah S, Stewart J, Staerkel G, Chen S, Gong Y, Guo M. EGFR and KRAS mutations in lung carcinoma: molecular testing by using cytology specimens. Cancer (Cancer Cytopathol). 2011;119:111-117.
4. da Cunha Santos G, Saieg MA, Geddie W, Leighl N. EGFR gene status in cytological samples of nonsmall cell lung carcinoma: controversies and opportunities. Cancer (Cancer Cytopathol). 2011;119: 80-91.
5. Ellison G, Zhu G, Moulis A, Dearden S, Speake G, McCormack R. EGFR mutation testing in lung cancer: A review of available methods and their use for analysis of tumour tissue and cytology samples. J Clin Pathol. 2013;66:79-89.
6. Pang B, Matthias D, Ong CW, et al. The positive impact of cytological specimens for EGFR mutation testing in non-small cell lung cancer: A single South East Asian laboratory's analysis of 670 cases. Cytopathology. 2012;23:229-236.
7. Rekhtman N, Brandt SM, Sigel CS, et al. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing. J Thorac Oncol. 2011;6:451-458.
8. Dejmek A, Zendehrokh N, Tomaszewska M, Edsjo A. Preparation of DNA from cytological material: effects of fixation, staining, and mounting medium on DNA yield and quality. Cancer (Cancer Cytopathol). 2013;121:344-353.
9. Killian JK, Walker RL, Suuriniemi M, et al. Archival fine-needle aspiration cytopathology (FNAC) samples: untapped resource for clinical molecular profiling. J Mol Diagn. 2010;12:739-745.
10. Groenen PJ, Blokx WA, Diepenbroek C, et al. Preparing pathology for personalized medicine: possibilities for improvement of the preanalytical phase. Histopathology. 2011;59:1-7.
11. Malapelle U, de Rosa N, Rocco D, et al. EGFR and KRAS mutations detection on lung cancer liquid-based cytology: A pilot study. J Clin Pathol. 2012;65:87-91.
12. Srinivasan M, Sedmak D, Jewell S. Effect of fixatives and tissue processing on the content and integrity of nucleic acids. Am J Pathol. 2002;161:1961-1971. (Pubitemid 35434840)